Patents by Inventor Sandrine Bourgeois

Sandrine Bourgeois has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Topical doxycycline composition
    Patent number: 11229597
    Abstract: The present invention relates to a novel pharmaceutical composition comprising doxycycline for topical application, in particular to the eye and eyelids. The invention also relates to this topical composition for use in the treatment of bacterial infections of the skin and mucous membranes.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: January 25, 2022
    Assignees: HORUS PHARMA, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Marion Dubald, Sandrine Bourgeois, Hatem Fessi, Martine Claret
  • TOPICAL DOXYCYCLINE COMPOSITION
    Publication number: 20210100739
    Abstract: The present invention relates to a novel pharmaceutical composition comprising doxycycline for topical application, in particular to the eye and eyelids. The invention also relates to this topical composition for use in the treatment of bacterial infections of the skin and mucous membranes.
    Type: Application
    Filed: April 3, 2018
    Publication date: April 8, 2021
    Inventors: Marion DUBALD, Sandrine BOURGEOIS, Hatem FESSI, Martine CLARET
  • Galenic formulation for colon-targeted delivery of active ingredients
    Patent number: 7833765
    Abstract: The invention concerns multiparticulate galenic formulations for oral administration and designed for colon targeted delivery of active principles selected from the group comprising enzymes capable of inactivating macrolides and the like, enzymes capable of inactivating quinolones and ?-lactamases.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: November 16, 2010
    Assignees: Da Volterra, Centre Nationale de la Recherche Scientifique
    Inventors: Sandrine Bourgeois, Elias Fattal, Antoine Andremont, Patrick Couvreur
  • GALENIC FORMULATION FOR COLON-TARGETED DELIVERY OF ACTIVE INGREDIENTS
    Publication number: 20090162339
    Abstract: The invention concerns multiparticulate galenic formulations for oral administration and designed for colon targeted delivery of active principles selected from the group comprising enzymes capable of inactivating macrolides and the like, enzymes capable of inactivating quinolones and ?-lactamases.
    Type: Application
    Filed: December 29, 2008
    Publication date: June 25, 2009
    Applicant: DA VOLTERRA
    Inventors: Sandrine Bourgeois, Elias Fattal, Antoine Andremont, Patrick Couvreur
  • Galenic pectinate formulation for colon-targeted delivery of antibiotic-inactivating enzymes and method of use thereof
    Patent number: 7485294
    Abstract: Forms of colonic delivery suited to be used orally and designed for colonic delivery of active ingredients selected from the group comprising enzymes capable of inactivating macrolide antibiotics and related compounds, enzymes capable of inactivating quinolones, and ?-lactamases.
    Type: Grant
    Filed: August 6, 2003
    Date of Patent: February 3, 2009
    Assignee: Da Volterra
    Inventors: Sandrine Bourgeois, Elias Fattal, Antoine Andremont, Patrick Couvreur
  • Colonic Delivery of Active Agents
    Publication number: 20080317666
    Abstract: Drug delivery devices that are orally administered, and that release active ingredients in the colon, are disclosed. In one embodiment, the active ingredients are those that inactivate antibiotics, such as macrolides, quinolones and beta-lactam containing antibiotics. One example of a suitable active agent is an enzyme such as beta-lactamases. In another embodiment, the active agents are those that specifically treat colonic disorders, such as Chrohn's Disease, irritable bowel syndrome, ulcerative colitis, colorectal cancer or constipation. The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethyleneimine. The high crosslink density of the polyethyleneimine is believed to stabilize the pectin beads for a sufficient amount of time such that a substantial amount of the active ingredients can be administered directly to the colon.
    Type: Application
    Filed: February 9, 2006
    Publication date: December 25, 2008
    Inventors: Elias Fattal, Antoine Andremont, Patrick Couvreur, Sandrine Bourgeois
  • Galenic formulation for colon targeted delivery of active principles
    Publication number: 20050249716
    Abstract: Forms of colonic delivery suited to be used orally and designed for colonic delivery of active ingredients selected from the group comprising enzymes capable of inactivating macrolide antibiotics and related compounds, enzymes capable of inactivating quinolones, and ?-lactamases.
    Type: Application
    Filed: August 6, 2003
    Publication date: November 10, 2005
    Inventors: Sandrine Bourgeois, Elias Fattal, Antoine Andremont, Patrick Couvreur